Heart rate variability (HRV) is an objective marker that provides insight into autonomic nervous system dynamics. There is conflicting evidence regarding the presence of HRV impairment in insomnia patients. Web-based databases were used to systematically search the literature for all studies that compared the HRV of insomnia patients to controls or reported the HRV of insomnia patients before and after an intervention. 22 relevant papers were identified. Study characteristics were summarised, HRV measures were extracted and a risk of bias assessment for each study was performed. We were limited in our ability to synthesise outcome measures and perform metaanalyses due to considerable differences in patient (and control) selection, study protocols, measurement and processing techniques and outcome reporting. Risk of bias was deemed to be high in the majority of studies. As such, we cannot confirm that HRV is reliably impaired in insomnia patients nor determine the HRV response to interventions. Whilst HRV impairment in insomnia is a widely accepted concept, it is not supported by empirical evidence. Large longitudinal studies incorporating 24-hour recordings are required to elucidate the precise nature of HRV dynamics in insomnia patients.
Introduction
Heart rate variability (HRV) describes the variation in time between consecutive heart beats, which is commonly referred to as the RR (R wave to R wave) or NN (normal beat to normal beat) interval.
Pacemaker cells located in the sinoatrial node of the heart possess autorhythmicity to maintain heart rate regularity. The heart rate (HR), however, is modulated by a number of physiological factors which alter autonomic nervous system control and increase variability at various frequencies. There are two prominent approaches for quantifying heart rate variation which use spectral or non-spectral techniques to generate HRV measures.
Non-spectral methods involve mathematical derivations of the NN interval. When taken from an electrocardiogram (ECG), this interval is determined by measuring the length in time between consecutive sinoatrial R-wave peaks. As many non-spectral derivations report the HRV in time (1) A description of these HRV measures can be found in Table 1 .
Spectral analysis of HRV enables the evaluation of frequency-domain measures. As parasympatheticmediated changes to HR occur more quickly than sympathetic adjustments, the use of spectral analysis to determine frequency can provide insight into autonomic nervous system dynamics. It has been accepted previously that low frequency (LF) activity is a correlate of parasympathetic and sympathetic activity whilst high frequency (HF) activity reflects parasympathetic activity only. As such the ratio between these (the LF/HF ratio) provides an estimate of sympathovagal balance which is the putative equilibrium of the sympathetic and parasympathetic systems. However, the physiological significance of the lower frequency bands (including LF and the LF/HF ratio) is now contested and caution is required when interpreting these measures. (2) (3) (4) This is further summarised in Table 1 . For a more detailed explanation of the physiological correlates of HRV measures refer to the previous review of Stein and Pu (5) .
Insert Table 1 The incorporation of HRV analysis during sleep has been a logical extension as the ECG is a component of overnight polysomnography (PSG). This has acted as a catalyst for further examination on the bidirectional relationship between autonomic nervous system activity and sleep physiology. (7) As such, it is not surprising that time and frequency-domain HRV measures, primarily from short recordings (i.e. less than 24 hours), are increasingly being reported in the sleep literature.
It is now known that HRV has circadian periodicity, significant alterations during the transition from wake to sleep and across sleep cycles. (8, 9) (10, 11) It is also known that there is a shift in sympathovagal balance between non rapid eye movement (NREM) and rapid eye movement (REM) sleep. (5, 9, 13) Accordingly, the research focus has shifted to investigating the associations between HRV, sleep disorders and their subsequent comorbidities and the incorporation of non-traditional HRV techniques. (5, 13, 14) Given the interplay between HRV and cardiac autonomic activity, the use of HRV in insomnia research may assist further investigation into the pathophysiology and potential health impacts of insomnia. Hyperarousal has been defined as 'a state of increased arousal at the physiological, cortical, cognitive or emotional level' (15) and hypothesised to contribute to the development, maintenance and 24-hour systemic sequelae of insomnia. (16) As such, the notion of physiological hyperarousal has been investigated by measuring HRV in insomnia patients despite the uncertain relationship between autonomic dysfunction, insomnia and cardiovascular disease. (16) With an estimated worldwide prevalence of 10%, insomnia is the most common sleep disorder. (15, 17, 18) Clinical diagnosis in accordance with the most recent diagnostic and statistical manual of mental disorders requires the patient to report difficulty initiating and/or maintaining sleep with subsequent daytime impairments greater than three nights per week and for at least three months. Whilst two reviews examining HRV, sleep and sleep disorders have been published previously they did not systematically synthesise the findings of the insomnia -HRV literature and we were aware of additional studies that were not included (5, 13) . Therefore, the aim of this review was to identify all 
Methods
We undertook an extensive search of the literature using CINAHL, EMBASE, Google Scholar, PubMed, Scopus and Web of Science databases on 25 th January 2016. Where possible the search incorporated a subject heading and key word strategy, combining "heart rate variability" or "HRV" and "insomnia".
The systematic search strategy was modified as necessary according to the database being searched, as shown in Appendix A. No limitations were used with the exception of Google Scholar where restrictions were used to exclude patents and citations. We had two main questions: 1) whether there were any differences in HRV of insomnia patients compared to controls (observational) and 2)
whether treatment interventions resulted in changes to the HRV of insomnia patients (interventional).
In order to be included for review, studies required the following:
1) Participants -humans ≥ 18 years old (observational) or insomnia patients (interventional)
2) Exposure -diagnosed with insomnia (observational) or a treatment for insomnia (interventional)
3) Comparisons -controls who were deemed to be good sleepers (observational) or the same group of patients compared before and after treatment or an ineffective or placebo treatment We included research studies that incorporated HRV measurements as either primary or secondary outcomes. Case studies and publications without original data were excluded from the review. The Page 9 of 30 interventional studies were not restricted to validated insomnia treatments, but rather any interventions that were conducted in insomnia patients and included pre-and post HRV measurements.
On completion of the database searches, duplicates were removed. All remaining studies were reviewed for eligibility by one author (KD) using the study title, abstract and, when required, full text. 
HRV measures
It was difficult to synthesise the findings of HRV measures reported in the observational studies.
Total power (TP) was the only HRV measure that provided unequivocal findings across observational studies -no significant differences were reported between insomnia patients and controls ( Table 3 ).
The second most consistent finding was that mean HR was found to be higher in insomnia patients Table 3 provides an overview of the HRV outcomes of the case-control studies.
Sleep onset (SO)
Heart rate variability activity during the transition from wakefulness to sleep is of particular interest given the changes in autonomic activity and the reported heightened symptomatology in insomnia patients at this time. (47) We identified two studies that measured HRV during the SO period (25), (33) and one that compared pre-, and post-sleep HRV measurements (21). de Zambotti et al. (25) found greater wake to sleep increases in HFnu which (matched by a greater wake to sleep HR reduction) in insomnia patients compared to controls, suggesting a greater increase in vagal control 
Daytime only
Daytime HRV testing of insomnia patients was undertaken in four studies with contradictory results. 
Risk of bias
Risk of bias of the observational studies is presented in Table 4 . There was considerable bias in many studies, with six studies not taking cases from the same population as controls. (21, 29, [33] [34] [35] 37) This was evident in the absence of a consistent methodology to match cases to controls in Table 2 .
The selection of controls was problematic with many not abiding to the suggested research diagnostic criteria for selection of insomnia controls. (48) Potential confounders, such as age, sex and comorbidities, were not often included despite the known impact upon HRV. The wide age range between studies is evident in Table 2 . The age range was also significant within studies, as was 
Insert Table 2, 3 & 4 about here

INTERVENTIONAL STUDIES
Demographics and data inclusion
All intervention studies were open label, single-arm clinical trials. Participant numbers were mostly small with the largest sample size of 31 patients. (42) The diverse age range is evident in Table 5 .
Between the five studies, four different diagnostic methods were used for classification of insomnia.
Insomnia severity of patients across studies was not able to be compared as one study provided scores for the insomnia severity index (39), two for the Athens insomnia scale (41, 42) and two for the Pittsburgh sleep quality index (known to measure sleep quality, not insomnia symptoms) (40, 43) . 
HRV measures
All interventions evoked some change in at least one HRV measure in insomnia patients ( Table 6 ). 
Risk of bias
No randomised control trials of the HRV of insomnia patients were identified. Therefore, no interventional studies achieved random sequence generation, (for the intervention) or undertook HRV findings were reported. Statistical under-powering of small studies must also be allowed for when considering the results. Risk of bias assessment for interventional studies is presented in Table   7 . 
Insert
Time of HRV recording
The HRV outcomes that were reported in Table 3 and Table 6 Bonnet and Arand (20) reported this measure to be increased during stage one, two and REM whereas Farina et al. (29) found this only in early N2. This made direct comparison between studies difficult.
Discussion
There are numerous reports in the literature that HRV is impaired in insomnia patients. These typically draw heavily on the findings of a small number of observational HRV research studies. (20, 21) These case-control studies have reported a decrease in some HRV measures related to parasympathetic activity in insomnia patients during sleep and these HRV impairments have been used to support a putative causal pathway for physiological hyperarousal and insomnia. (51) This would be a logical inference; however, it is challenging to draw firm conclusions from the studies in our review, with nearly half of the observational studies reporting no significant HRV difference between insomnia patients and controls. In addition, HRV was measured during a multitude of different states (wake, sleep onset, sleep stages, post-sleep wake), with a lack of consistent findings across studies. When between-group differences were evident, they were often in dissimilar time and frequency-domain HRV measures and not replicated consistently in other studies. Furthermore, there appears to be insufficient evidence to determine if HRV in insomnia patients is impaired during the day or how it may vary across the 24-hour cycle. We therefore suggest that the evidence for HRV impairment in insomnia is imperfect and that further studies are required.
There were only five intervention studies and as these modalities were not synonymous it was difficult to draw any conclusions from the data. Only one study examined HRV before and after the gold-standard treatment for insomnia, cognitive behavioural therapy and this was in a modest sample of 26 patients. (52-56) Interestingly, despite a uniform increase in HR in insomnia patients in some but not all case-control studies (refer to Highly disparate populations were investigated across the studies in our review. In many studies cases and controls were retrospectively selected and despite providing statistical comparison between the groups, there was a lack of case-match methodology reporting. Sample sizes were generally small across all studies which limited the generalisability of the findings. The largest of the studies reviewed had 85 cases and 55 controls, derived from non-comparable populations. (29) It is likely that many studies were underpowered and this may have impacted on the findings.
Several diagnostic methods and insomnia severity scales were used, making it difficult to compare populations between studies. An example of this is the use of sleep efficiency for insomnia patient eligibility. Whilst two studies only included insomnia patients when PSG sleep efficiency was 85% or less, others included insomnia patients with high sleep efficiency values 90% (SD 4) and 91% (SD 5) respectively. (20, 26, 27, 34) Only one study classified the severe insomnia phenotype of total sleep time less than 6 hours. (45) This study quantified short-sleep duration insomnia using PSG-derived sleep efficiency percentage, whereby those with a sleep efficiency of less than 85 were considered to be short-sleepers. This subgroup analysis revealed differences between short-sleeping insomniacs and controls (refer to Table 3 ). However, no within-group comparisons were made between these insomnia patients i.e. short sleep duration insomnia patients and those with a longer sleep time.
Although it was not the focus of our current review, we are not aware of any other research that has been published that has used HRV to phenotype insomnia patients.
Sex, sex-ratio and age of participants and controls were diverse. This is of particular concern given the known influence imparted on HRV by sex and/or age. (57, 58) Evidence from a recent metaanalysis found females to have both higher mean HR and greater vagal activity evident in a number of HRV measures. (58) It must be noted that the authors of this meta-analysis also deduced that 'mean heart rate alone provides little to no insight into risk for cardiovascular disease'. (58) Researchers should also be mindful of possible HRV implications from co-morbid sleep disorders (particularly sleep obstructive sleep apnoea) when designing and reviewing studies particularly given the possible impact that these have on HRV. (5, 59) Other potential confounders such as stimulants, medications and medical comorbidities were often unreported and may have influenced the HRV findings.
Considering Whilst all studies found some degree of altered associations between HRV and EEG in insomnia patients compared to controls, it remains unclear whether this is a trait of insomnia patients or a consequence of the disorder.
Limitations of our review include the use of two different risk of bias assessment tools and this was performed by one author only. No attempts were made to contact study authors when method of HRV analysis was unclear. We were unable to perform a meta-analysis due to the difficulty collating findings arising from studies of different designs, study populations, measurement techniques and analyses.
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A number of studies in this review have drawn conclusions about the associations between physiological hyperarousal, HRV and cardiovascular disease, often in reference to the study results. It is tempting to deduce that an increase in sympathetic-related HRV measures will be mirrored by a decrease in parasympathetic-related HRV measures and that this explains the autonomic dysfunction. However, the traditional notion of an antagonistic autonomic nervous system is now In conclusion, our critical review of the insomnia-HRV research studies revealed varied results and a lack of consistent HRV findings in insomnia patients. We suggest that longitudinal studies using repeat measures with large sample sizes are required to determine the relationship, if present, between HRV and insomnia.
Practice Points
1) There is inconsistent evidence to suggest that heart rate variability is impaired in insomnia.
2) We cannot deduce if or how insomnia interventions alter heart rate variability and autonomic dysfunction.
3) Measurements from short-term heart rate recordings cannot be compared to 24-hour recordings, thus the use of heart rate variability as a prognostic tool for cardiovascular disease in insomnia patients is not yet possible.
Research Agenda
1) Develop recommendations for the measurement, analysis and reporting of HRV in in sleep and circadian research in order to aid interpretation, reproducibility and cross-comparison.
2) Perform large longitudinal studies of insomnia patients and controls that incorporate 24-hour recordings to determine the heart rate variability of insomnia patients across the sleep-wake cycle.
3) Consider the retrospective and prospective validation of the cardiovascular disease predictive power of heart rate variability measures in insomnia patients and appropriately matched controls (possibly via a nested case-control study within a large cardiovascular disease cohort study). 4) Explore whether heart rate variability can be used to phenotype the heterogeneous insomnia population.
